New 'Off-the-Shelf' cell therapy takes on Hard-to-Treat cancers
NCT ID NCT07589530
First seen May 17, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study tests a new treatment called EB-NK-301 for adults with advanced solid tumors that have stopped responding to standard therapies. EB-NK-301 uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 on cancer cells. The main goals are to check the treatment's safety and find the best dose, while also looking at whether it can shrink tumors. About 60 participants will receive the cells after a short course of chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.